TheraVet SA (ALVET.PA)
EUR 0.11
(-0.46%)
EUR 0.11
(-0.46%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.48 Million EUR | -25.02% |
| 2022 | 1.98 Million EUR | 9.8% |
| 2021 | 1.8 Million EUR | 4.94% |
| 2020 | 1.71 Million EUR | 218.47% |
| 2019 | 539.73 Thousand EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.86 Million EUR | 25.87% |
| 2024 Q2 | 1.86 Million EUR | 0.0% |
| 2023 Q4 | 1.48 Million EUR | 0.0% |
| 2023 Q2 | 1.35 Million EUR | -0.0% |
| 2023 Q1 | 1.35 Million EUR | -31.47% |
| 2023 FY | 1.48 Million EUR | -25.02% |
| 2023 Q3 | 1.48 Million EUR | 9.4% |
| 2022 Q1 | 1.6 Million EUR | -11.25% |
| 2022 Q4 | 1.98 Million EUR | -0.0% |
| 2022 Q3 | 1.98 Million EUR | 23.73% |
| 2022 Q2 | 1.6 Million EUR | 0.0% |
| 2022 FY | 1.98 Million EUR | 9.8% |
| 2021 Q4 | 1.8 Million EUR | 0.0% |
| 2021 Q1 | 1.72 Million EUR | 0.29% |
| 2021 Q2 | 1.72 Million EUR | -0.0% |
| 2021 Q3 | 1.8 Million EUR | 4.64% |
| 2021 FY | 1.8 Million EUR | 4.94% |
| 2020 Q1 | - EUR | 0.0% |
| 2020 FY | 1.71 Million EUR | 218.47% |
| 2020 Q3 | 1.71 Million EUR | 85.25% |
| 2020 Q4 | 1.71 Million EUR | 0.0% |
| 2020 Q2 | 927.89 Thousand EUR | 0.0% |
| 2019 FY | 539.73 Thousand EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ABIONYX Pharma SA | 6.91 Million EUR | 78.516% |
| ABIVAX Société Anonyme | 131.05 Million EUR | 98.867% |
| Adocia SA | 31.87 Million EUR | 95.34% |
| Aelis Farma SA | 13.08 Million EUR | 88.647% |
| Biophytis S.A. | 15.84 Million EUR | 90.63% |
| Advicenne S.A. | 24.37 Million EUR | 93.908% |
| genOway Société anonyme | 14.45 Million EUR | 89.73% |
| IntegraGen SA | 5.97 Million EUR | 75.166% |
| Medesis Pharma S.A. | 6.42 Million EUR | 76.892% |
| Neovacs S.A. | 3.71 Million EUR | 59.996% |
| NFL Biosciences SA | 3.62 Million EUR | 58.986% |
| Plant Advanced Technologies SA | 6.78 Million EUR | 78.105% |
| Quantum Genomics Société Anonyme | 3.31 Million EUR | 55.138% |
| Sensorion SA | 13.22 Million EUR | 88.773% |
| Theranexus Société Anonyme | 5.01 Million EUR | 70.396% |
| TME Pharma N.V. | 2.78 Million EUR | 46.679% |
| Valbiotis SA | 13.7 Million EUR | 89.167% |
| Valerio Therapeutics Société anonyme | 20.46 Million EUR | 92.745% |
| argenx SE | 402.79 Million EUR | 99.631% |
| BioSenic S.A. | 32.26 Million EUR | 95.397% |
| Celyad Oncology SA | 9.97 Million EUR | 85.117% |
| DBV Technologies S.A. | 38.74 Million USD | 96.167% |
| Galapagos NV | 1.56 Billion EUR | 99.905% |
| Genfit S.A. | 105.92 Million EUR | 98.598% |
| GeNeuro SA | 20.13 Million EUR | 92.627% |
| Hyloris Pharmaceuticals SA | 8.61 Million EUR | 82.757% |
| Innate Pharma S.A. | 132.29 Million EUR | 98.877% |
| Inventiva S.A. | 101.59 Million EUR | 98.538% |
| MaaT Pharma SA | 22.46 Million EUR | 93.39% |
| MedinCell S.A. | 77.77 Million EUR | 98.091% |
| Nanobiotix S.A. | 95.74 Million EUR | 98.449% |
| Onward Medical N.V. | 25.69 Million EUR | 94.221% |
| Oryzon Genomics S.A. | 25.12 Million EUR | 94.09% |
| OSE Immunotherapeutics SA | 59.07 Million EUR | 97.486% |
| Oxurion NV | 19.73 Million EUR | 92.476% |
| Pharming Group N.V. | 228.28 Million EUR | 99.35% |
| Poxel S.A. | 53.9 Million EUR | 97.245% |
| GenSight Biologics S.A. | 34.72 Million EUR | 95.724% |
| Transgene SA | 26.51 Million EUR | 94.4% |
| Financière de Tubize SA | 123.65 Million EUR | 98.799% |
| UCB SA | 6.56 Billion EUR | 99.977% |
| Valneva SE | 341.14 Million EUR | 99.565% |
| Vivoryon Therapeutics N.V. | 4.54 Million EUR | 67.341% |